Livforsakringsbolaget Skandia Omsesidigt Has $8.12 Million Stake in Tenet Healthcare Corporation $THC

Livforsakringsbolaget Skandia Omsesidigt raised its position in shares of Tenet Healthcare Corporation (NYSE:THC) by 11.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,050 shares of the company’s stock after purchasing an additional 4,400 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Tenet Healthcare were worth $8,124,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Norges Bank purchased a new position in shares of Tenet Healthcare during the fourth quarter valued at $248,494,000. Wellington Management Group LLP lifted its stake in Tenet Healthcare by 1,114.2% in the 4th quarter. Wellington Management Group LLP now owns 1,135,801 shares of the company’s stock worth $225,706,000 after acquiring an additional 1,042,260 shares in the last quarter. Boston Partners grew its stake in Tenet Healthcare by 38.8% during the 3rd quarter. Boston Partners now owns 3,147,555 shares of the company’s stock valued at $638,958,000 after acquiring an additional 880,413 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Tenet Healthcare by 62.3% in the 3rd quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock valued at $380,989,000 after purchasing an additional 720,160 shares during the period. Finally, Alliancebernstein L.P. lifted its position in shares of Tenet Healthcare by 375.7% in the second quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock worth $139,085,000 after purchasing an additional 624,125 shares in the last quarter. Institutional investors and hedge funds own 95.44% of the company’s stock.

Tenet Healthcare Stock Performance

THC stock opened at $183.60 on Wednesday. The firm has a 50 day moving average of $184.20 and a two-hundred day moving average of $197.55. Tenet Healthcare Corporation has a 12 month low of $146.60 and a 12 month high of $247.21. The company has a market capitalization of $15.81 billion, a price-to-earnings ratio of 9.55, a P/E/G ratio of 1.60 and a beta of 1.27. The company has a quick ratio of 1.30, a current ratio of 1.36 and a debt-to-equity ratio of 1.96.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings results on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, beating analysts’ consensus estimates of $4.21 by $0.61. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. The business had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.39 billion. During the same quarter last year, the firm earned $4.36 EPS. Tenet Healthcare’s revenue for the quarter was up 2.6% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. As a group, equities analysts anticipate that Tenet Healthcare Corporation will post 17.61 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on THC. Wells Fargo & Company upped their price objective on shares of Tenet Healthcare from $213.00 to $231.00 and gave the company an “overweight” rating in a research note on Monday. TD Cowen lowered their price target on shares of Tenet Healthcare from $242.00 to $233.00 and set a “buy” rating on the stock in a report on Monday, June 22nd. Robert W. Baird dropped their price target on shares of Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 5th. Wall Street Zen cut Tenet Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 11th. Finally, Guggenheim lowered their target price on Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Eighteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Tenet Healthcare presently has an average rating of “Moderate Buy” and an average target price of $245.37.

Insider Activity

In related news, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total value of $532,050.00. Following the transaction, the director directly owned 24,805 shares of the company’s stock, valued at approximately $4,399,166.75. This trade represents a 10.79% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director J Robert Kerrey sold 5,638 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total value of $983,943.76. Following the completion of the sale, the director owned 16,804 shares of the company’s stock, valued at approximately $2,932,634.08. This trade represents a 25.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.97% of the stock is owned by company insiders.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.